Inclusion Criteria:

- Adult subjects, aged 18 to 75 years old, inclusive

- Subjects with acromegaly defined as documented evidence of GH-secreting pituitary
tumor that is abnormally responsive to glucose who are currently receiving a
somatostatin analog

- Subjects able and willing to comply with the requirements of the protocol

- Subjects able to swallow capsules

- Subjects able to understand and sign written informed consent to participate in the
study

Exclusion Criteria:

- Symptomatic cholelithiasis

- Received pituitary radiotherapy within ten years prior to screening

- Undergone pituitary surgery within the prior 6 months

- Clinically significant GI, renal or hepatic disease

- Known allergy or hypersensitivity to any of the test compounds or materials

- Life expectancy of less than 2 years

- Uncontrolled diabetes

- Defects in visual fields due to optic chiasmal compression

- Female patients who are pregnant or lactating

- Female patients who are of childbearing potential

- History of immunocompromise, including a positive HIV test result (ELISA and Western
blot)

- History of alcohol or drug abuse

- Intake of an investigational drug within 30 days before patient inclusion in this
study